Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso

• Autorzy: Tinto H. , Valea I. , Ouedraogo J.-B. , Guiguemde T.R.
• Języki publikacji: EN

Abstrakty

EN

The history of drug resistance to the previous antimalarial drugs, and the potential for resistance to evolve to Artemisinin-based combination therapies, demonstrates the necessity to set-up a good surveillance system in order to provide early warning of the development of resistance. Here we report a review summarizing the history of the surveillance of drug resistance that led to the policy change in Burkina Faso. The first Plasmodium falciparum Chloroquine-Resistance strain identified in Burkina Faso was detected by an in vitro test carried out in Koudougou in 1983. Nevertheless, no further cases were reported until 1987, suggesting that resistant strains had been circulating at a low prevalence before the beginning of the systematic surveillance system from 1984. We observed a marked increase of Chloroquine-Resistance in 2002–2003 probably due to the length of follow-up as the follow-up duration was 7 or 14 days before 2002 and 28 days from 2002 onwards. Therefore, pre-2002 studies have probably under-estimated the real prevalence of Chloroquine-Resistance by not detecting the late recrudescence. With a rate of 8.2% treatment failure reported in 2003, Sulfadoxine-Pyrimethamine was still efficacious for the treatment of uncomplicated malaria in Burkina Faso but this rate might rapidly increase as the result of its spreading from neighboring countries and due to its current use for both the Intermittent Preventive Treatment in pregnant women and Seasonal Malaria Chemoprophylaxis. The current strategy for the surveillance of the Artemisinin-based combination treatments resistance should build on lessons learnt under the previous period of 20 years surveillance of Chloroquine and Sulfadoxine-Pyrimethamine resistance (1994–2004). The most important aspect being to extend the number of sentinel sites so that data would be less patchy and could help understanding the dynamic of the resistance.

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2016
• Tom: 62
• Numer: 1
• Opis fizyczny: p.17–24,fig.,ref.

Twórcy

autor

Tinto H.

• Institut de Recherche en Sciences de la Sante - Unite de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso
• Centre Muraz, Bobo-Dioulasso, Burkina Faso

autor

Valea I.

• Institut de Recherche en Sciences de la Sante - Unite de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso
• Centre Muraz, Bobo-Dioulasso, Burkina Faso

autor

Ouedraogo J.-B.

• Institut de Recherche en Sciences de la Sante - Unite de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso

autor

Guiguemde T.R.

• Centre Muraz, Bobo-Dioulasso, Burkina Faso

Bibliografia

• [1] WHO. World malaria report 2011. Geneva: WHO, 2011. 2011.
• [2] Maude R.J., Pontavornpinyo W., Saralamba S., Aguas R., Yeung S., Dondorp A.M. et al. 2009. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malaria Journal 8: 31. doi:10.1186/1475-2875-8-31.
• [3] Rogers W.O., Sem R., Tero T., Chim P., Lim P., Muth S. et al. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malaria Journal 8: 10.
• [4] Noedl H., Se Y., Sriwichai S., Schaecher K., Teja-Isavadharm P., Smith B. et al. 2010. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clinical Infectious Diseases 51: e82-89. doi:10.1086/657120.
• [5] Lim P., Alker A.P., Khim N., Shah N.K., Incardona S., Doung S. et al. 2009. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malaria Journal 8: 11.
• [6] Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J. et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine 361: 455-467. doi:10.1056/NEJMoa0808859.
• [7] Beshir K.B., Sutherland C.J., Sawa P., Drakeley C.J., Okell L., Mweresa C.K. et al. 2013. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. Journal of Infectious Diseases 208: 2017-2024. doi:10.1093/infdis/jit431.
• [8] Borrmann S., Sasi P., Mwai L., Bashraheil M., Abdallah A., Muriithi S. et al. 2011. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 6: e26005. doi:10.1371/journal.pone.0026005.
• [9] Gharbi M., Flegg J.A., Hubert V., Kendjo E., Metcalf J.E., Bertaux L. et al. 2013. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malaria Journal 2: 35. doi:10.1186/1475-2875-12-35.
• [10] Mita T., Tanabe K. 2012. Evolution of Plasmodium falciparum drug resistance: Implications for the development and containment of artemisinin resistance. Japanese Journal of Infectious Diseases 65: 465-475. doi:10.7883/yoken.65.465.
• [11] Gansané A., Nébié I., Soulama I., Tiono A., Diarra A., Konaté A.T. et al. 2009. Change of antimalarial first-line treatment in Burkina Faso in 2005. Bulletin de la Société de Pathologie Exotique 1990 102: 31-35.
• [12] Zongo I., Tinto H., Drabo K.M., Rouamba N., Guiguemdé T.R. 2005. Historique de la chloroquino résistance de 2001 à 2004 au Burkina Faso: les raisons d’un changement de la politique nationale de traitement du paludisme simple 30: 47-53.
• [13] Sibley C.H., Guerin P.J., Ringwald P. 2010. Monitoring antimalarial resistance: launching a cooperative effort. Trends in Parasitology 26: 221-224.
• [14] Tinto H., Zoungrana E.B., Coulibaly S.O., Ouedraogo J.B., Traoré M., Guiguemde T.R. et al. 2002. Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000. Tropical Medicine and International Health 7: 925-930. doi:10.1046/j.1365-3156.2002.00952.x.
• [15] EDSBF-MICSIV 2012. Institut National de la Statistique et de la Démographie, Ouagadougou, Burkina Faso.
• [16] Derra K., Rouamba E., Kazienga A., Ouedraogo S., Tahita M.C., Sorgho H. et al. 2012. Profile: Nanoro Health and Demographic Surveillance System. International Journal of Epidemiology 41:1293-1301. doi:10.1093/ije/dys159.
• [17] Ouedraogo J.B., Guiguemde T.R., Somda A., Gbary A.R., Baudon D. 1987. Une méthode simplifiée de surveillance active de la chloroquinosensibilité de Plasmodium falciparum par les centres de santé périphériques. Medecine d’Afrique Noire 34: 711-717.
• [18] Baudon D., Decouvoux Roux J., Sondo B. 1984. Etude de la sensibilité de P. falciparum ala chloroquine dans une savane de Haute-Volta apaludisme hyper-endémique: utilisation des tests in vivo et in vitro. Bulletin de la Société de Pathologie Exotique 77: 658-665.
• [19] Payne D. 1982. Aspects pratiques des épreuves in vivo de la sensibilité des plasmodies humaines aux antipaludiques. WHO/MAL/82,1986, Genève.
• [20] Baudon D., Guiguemde T.R., Ouedraogo J.B. 1987. Surveillance de la sensibilite de Plasmodium falciparum a la chloroquine en Afrique de l’Ouest: interet de l’utilisation de tests in vivo a 5 et 10 mg/kg. Bulletin de la Société de Pathologie Exotique 80: 469-476.
• [21] Ouédraogo J.B., Lamizana L., Toe A.C.R., Kumilien S., Gbary A.R., Guigemdé T.R. et al. 1991. Emergence du Paludisme chimiorésistant au Burkina Faso. Medecine d’Afrique Noire 38.
• [22] Ouédraogo J.B., Guiguemdé T.R., Gbary A.R. 1990. Surveillance passive de la chimiosensibilité palustre à Bobo-Dioulasso ( Burkina Faso). Medecine d’Afrique Noire 37: 261-264.
• [23] Ouédraogo J.B., Dutheil Y., Tinto H., Traoré B., Zampa H., Tall F. et al. 1998. In vitro sensitivity of Plasmodium falciparum to halofantrine compared with chloroquine, quinine and mefloquine in the region of Bobo-Dioulasso, Burkina Faso (West Africa). Tropical Medicine and International Health 3: 381-384.
• [24] Del Nero L., Lamizana L., Pietra V., Nebié I. 1994. Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Oubritenga province, Burkina Faso. Parassitologia 36: 287-293.
• [25] Tinto H., Sanou B., Erhart A., D’Alessandro U., Ouédraogo J.B., Guiguemdé T.R. 2006. [In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine pyrimethamine in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs]. Bulletin de la Societe de Pathologie Exotique 99:161-165 (in French).
• [26] Tinto H., Ouédraogo J.B., Zongo I., van Overmeir C., van Marck E., Guiguemdé T.R. et al. 2007. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. American Journal of Tropical Medicine and Hygiene 76: 608-613.
• [27] Guiguemdé T.R., Gbary A.R., Ouedraogo J.B., Gaybor A.., Lamizana L, Maïga A.S. et al. 1991. Point actuel sur la chimiorésistance du paludisme des sujets autochtones dans les états de l’OCCGE (Afrique de l’Oest). Annales de la Societe Belge de Médecine Tropicale 71: 199-207.
• [28] Guiguemde T.R., Aouba A., Ouedraogo J.B., Lamizana L. 1994. Ten-year surveillance of drugresistant malaria in Burkina Faso (1982-1991). American Journal of Tropical Medicine and Hygiene 50: 699-704.
• [29] Stepniewska K., Taylor W.R., Mayxay M., Price R., Smithuis F., Guthmann J.P. et al. 2004. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrobial Agents and Chemotherapy 48: 4271-4280. doi:10.1128/AAC.48.11.4271-4280.2004.
• [30] Curtis J., Duraisingh M.T., Trigg J.K., Mbwana H., Warhurst D.C., Curtis C.F. 1996. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene 90: 678-680. doi:10.1016/S0035-9203(96)90432-0.
• [31] Deloron P., Mayombo J., Cardinal A.Le., Mezui-Me-Ndong J., Bruzi-Baert C., Lekoulou F. et al. 2000. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Transactions of the Royal Society of Tropical Medicine and Hygiene 94:188-190.
• [32] Plowe C.V., Cortese J.F., Djimde A., Nwanyanwu O.C., Watkins W.M., Winstanley P.A. et al. 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethaminesulfadoxine use and resistance. Journal of Infectious Diseases 176:1590-1596. doi:10.1086/514159.
• [33] Driessen G.J.A., Van Kerkhoven S., Schouwenberg B.J.J.W., Bonsu G., Verhave J.P. 2002. Sulpha doxine /pyrimethamine: An appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age. Tropical Medicine and International Health 7: 577-583.
• [34] Henry M.C., Niangue J., Kone M. 2002. [Which medication should be used to treat uncomplicated malaria when chloroquine becomes ineffective in Western Cote d’Ivoire?]. Medecine Tropicale (Mars) 62: 55-57 (In French).
• [35] World Health Organization. Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in children: A field guide 2013:1-56.
• [36] Headquarters WHO. Technical Expert Group meeting on intermittent preventive treatment in pregnancy (IPTp) 2007:11-13.

Identyfikatory

DOI

10.17420/ap6201.27